INmune Bio Correlations
| INMB Stock | USD 1.54 0.03 1.99% |
The current 90-days correlation between INmune Bio and CEL SCI Corp is 0.04 (i.e., Significant diversification). The correlation of INmune Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
INmune Bio Correlation With Market
Good diversification
The correlation between INmune Bio and DJI is -0.01 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding INmune Bio and DJI in the same portfolio, assuming nothing else is changed.
Moving together with INmune Stock
Moving against INmune Stock
| 0.39 | CVX | Chevron Corp Sell-off Trend | PairCorr |
Related Correlations Analysis
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between INmune Stock performing well and INmune Bio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze INmune Bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CVM | 4.60 | (0.51) | 0.00 | (0.31) | 0.00 | 10.19 | 30.91 | |||
| BRNS | 3.07 | (0.64) | 0.00 | 4.12 | 0.00 | 5.71 | 24.01 | |||
| ALGS | 4.60 | 0.08 | 0.01 | 0.25 | 5.13 | 11.50 | 28.43 | |||
| TPST | 4.78 | (1.75) | 0.00 | (1.81) | 0.00 | 7.62 | 52.01 | |||
| OKUR | 3.83 | (0.24) | 0.00 | (0.17) | 0.00 | 7.76 | 25.44 | |||
| MRSN | 7.16 | 3.42 | 0.82 | 3.62 | 2.27 | 7.25 | 210.61 | |||
| SKYE | 4.80 | (1.02) | 0.00 | (0.99) | 0.00 | 10.19 | 25.49 | |||
| XFOR | 3.18 | (0.05) | 0.00 | 0.22 | 0.00 | 7.57 | 23.09 | |||
| PDSB | 4.13 | (0.42) | 0.00 | (0.12) | 0.00 | 8.08 | 27.78 | |||
| FGEN | 2.66 | (0.26) | 0.00 | (0.31) | 0.00 | 4.33 | 28.75 |
INmune Bio Corporate Management
| Christopher Barnum | Head Neuroscience | Profile | |
| BSc FRCPath | Chief Officer | Profile | |
| Mark Lowdell | Chief Officer | Profile | |
| Daniel Carlson | Head Relations | Profile | |
| Raymond MD | President, CoFounder | Profile | |
| Joshua Esq | General Counsel | Profile |